267 related articles for article (PubMed ID: 27196896)
1. Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes.
Saisho Y
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196896
[TBL] [Abstract][Full Text] [Related]
2. Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes.
Okuno Y; Komada H; Sakaguchi K; Nakamura T; Hashimoto N; Hirota Y; Ogawa W; Seino S
Metabolism; 2013 Oct; 62(10):1470-6. PubMed ID: 23831440
[TBL] [Abstract][Full Text] [Related]
3. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes.
Shim WS; Kim SK; Kim HJ; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
Eur J Endocrinol; 2006 Oct; 155(4):615-22. PubMed ID: 16990662
[TBL] [Abstract][Full Text] [Related]
4. Serum bilirubin concentrations are positively associated with serum C-peptide levels in patients with Type 2 diabetes.
Chung JO; Cho DH; Chung DJ; Chung MY
Diabet Med; 2014 Nov; 31(11):1316-22. PubMed ID: 24910105
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic hyperplasia after gastric bypass surgery in a GK rat model of non-obese type 2 diabetes.
Zhou X; Qian B; Ji N; Lui C; Liu Z; Li B; Zhou H; Yan C
J Endocrinol; 2016 Jan; 228(1):13-23. PubMed ID: 26468390
[TBL] [Abstract][Full Text] [Related]
6. Association of serum pancreatic derived factor (PANDER) with beta-cell dysfunction in type 2 diabetes mellitus.
Shehata MM; Kamal MM; El-Hefnawy MH; El-Mesallamy HO
J Diabetes Complications; 2017 Apr; 31(4):748-752. PubMed ID: 28161382
[TBL] [Abstract][Full Text] [Related]
7. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
[TBL] [Abstract][Full Text] [Related]
8. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
[TBL] [Abstract][Full Text] [Related]
9. Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area.
Fujita Y; Kozawa J; Iwahashi H; Yoneda S; Uno S; Yoshikawa A; Okita K; Eguchi H; Nagano H; Imagawa A; Shimomura I
Endocr J; 2015; 62(4):329-37. PubMed ID: 25740613
[TBL] [Abstract][Full Text] [Related]
10. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations.
Polonsky KS; Rubenstein AH
Diabetes; 1984 May; 33(5):486-94. PubMed ID: 6373457
[TBL] [Abstract][Full Text] [Related]
11. [The clinical utility of C-peptide measurement in diabetology].
Otto-Buczkowska E
Pediatr Endocrinol Diabetes Metab; 2015; 20(2):63-8. PubMed ID: 26615015
[TBL] [Abstract][Full Text] [Related]
12. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9.
Hernandez M; Mollo A; Marsal JR; Esquerda A; Capel I; Puig-Domingo M; Pozzilli P; de Leiva A; Mauricio D;
BMC Endocr Disord; 2015 Jan; 15():1. PubMed ID: 25572256
[TBL] [Abstract][Full Text] [Related]
13. Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes.
Bowman P; McDonald TJ; Shields BM; Knight BA; Hattersley AT
Diabet Med; 2012 Jan; 29(1):90-3. PubMed ID: 21883437
[TBL] [Abstract][Full Text] [Related]
14. Improved glycemic control enhances the incretin effect in patients with type 2 diabetes.
An Z; Prigeon RL; D'Alessio DA
J Clin Endocrinol Metab; 2013 Dec; 98(12):4702-8. PubMed ID: 24092826
[TBL] [Abstract][Full Text] [Related]
15. Postprandial metabolic responses to mixed versus liquid meal tests in healthy men and men with type 2 diabetes.
Brodovicz KG; Girman CJ; Simonis-Bik AM; Rijkelijkhuizen JM; Zelis M; Bunck MC; Mari A; Nijpels G; Eekhoff EM; Dekker JM
Diabetes Res Clin Pract; 2011 Dec; 94(3):449-55. PubMed ID: 21955958
[TBL] [Abstract][Full Text] [Related]
16. Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance.
Sheikh S; Gudipaty L; De Leon DD; Hadjiliadis D; Kubrak C; Rosenfeld NK; Nyirjesy SC; Peleckis AJ; Malik S; Stefanovski D; Cuchel M; Rubenstein RC; Kelly A; Rickels MR
Diabetes; 2017 Jan; 66(1):134-144. PubMed ID: 27495225
[TBL] [Abstract][Full Text] [Related]
17. Residual C-peptide in type 1 diabetes: what do we really know?
VanBuecken DE; Greenbaum CJ
Pediatr Diabetes; 2014 Mar; 15(2):84-90. PubMed ID: 24645775
[TBL] [Abstract][Full Text] [Related]
18. Circulating adiponectin concentration is inversely associated with glucose tolerance and insulin secretion in people with newly diagnosed diabetes.
Weber KS; Strassburger K; Pacini G; Nowotny B; Müssig K; Szendroedi J; Herder C; Roden M;
Diabet Med; 2017 Feb; 34(2):239-244. PubMed ID: 27770592
[TBL] [Abstract][Full Text] [Related]
19. C-peptide measurement: methods and clinical utility.
Bonser AM; Garcia-Webb P
Crit Rev Clin Lab Sci; 1984; 19(4):297-352. PubMed ID: 6373142
[TBL] [Abstract][Full Text] [Related]
20. Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency.
Ciresi A; Cicciò F; Radellini S; Giordano C
Growth Horm IGF Res; 2016 Aug; 29():71-77. PubMed ID: 27235725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
